Welcome to our dedicated page for UTAH MEDICAL PRODUCTS SEC filings (Ticker: UTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UTAH MEDICAL PRODUCTS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UTAH MEDICAL PRODUCTS's regulatory disclosures and financial reporting.
Paul O. Richins, a director of Utah Medical Products, sold 100 shares of the company's common stock on 08/25/2025 at $60.34 per share. After the sale he beneficially owns 21,136 shares indirectly, held across a family trust, a personal IRA, his spouse's IRA and his sons' accounts: 18,948 shares in the Richins Family Trust, 1,245 in his spouse's IRA, 443 by his sons and 500 in his own IRA. The Form 4 indicates the filing was made by one reporting person and is signed by Mr. Richins.
Brandes Investment Partners, L.P. reports beneficial ownership of 271,537 common shares of Utah Medical Products, representing 7.39% of the class as stated in Item 4. The filing shows Brandes holds shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power, indicating it does not exercise unilateral control.
The statement is filed on Schedule 13G/A and classifies the reporting person as IA, PN (investment adviser/portfolio manager). The filer certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Utah Medical Products (UTMD) reported Q2 2025 net sales of $9,953 thousand, down 4.3% from $10,400 in Q2 2024, and first-half sales of $19,663 thousand, down 9.6% year-over-year. Gross profit fell to $5,595 thousand (56.2% margin) from $6,253 thousand (60.1%), driven by lower volumes, an unfavorable product mix in Ireland and reduced orders from former large OEM customer PendoTECH. Net income was $3,048 thousand in Q2 and $6,089 thousand for 1H 2025; diluted EPS were $0.94 and $1.86, respectively.
The company remains well capitalized with $82.2 million in cash and investments, no debt, ongoing dividends and opportunistic share repurchases (119,255 shares repurchased in 1H 2025 for $6.7 million). Management expects full-year PendoTECH sales to be about $2.0 million lower than 2024, is tracking adjusted EBITDA near targets, and highlights potential OUS tariff and distributor-timing risks that could affect 2H results.